Case Series: COVID-19 in African American Patients With Sarcoidosis

Frontiers in Medicine

article

Michael Manansala¹  Christian Ascoli¹  Ana Goico Alburquerque¹  David Perkins¹  Mehdi Mirsaedi²  Patricia Finn¹  Nadera J. Sweiss¹ 

[1] Department of Internal Medicine, University of Illinois at Chicago, United States;Miller School of Medicine, University of Miami, United States

关键词: sarcoidosis;    COVID;    19;    immunosuppression;    DMARDs;    African American (AA);    SAR-CoV-2;   

DOI  :  10.3389/fmed.2020.588527

学科分类：社会科学、人文和艺术（综合）

来源: Frontiers

【 摘 要 】

Data on the clinical presentation and outcomes of sarcoidosis patients with coronavirus disease 19 (COVID-19) are scarce. In this case series, we identified 5 out of 238 sarcoidosis patients who are enrolled in an ongoing longitudinal observational study who developed COVID-19 during the study period and follow their clinical course. Four patients recovered completely, whereas one patient expired during hospital admission. Our preliminary experience suggests that African American patients with chronic sarcoidosis treated with disease-modifying anti-rheumatic drugs (DMARDs) or anti-tumor necrosis factor (TNF) therapy do not seem to be at increased risk of respiratory or life-threatening complications from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) compared with the general population, although at the present time, we advocate for maintaining a high level of vigilance and strict follow-up in this patient population.

【 授权许可】

CC BY